Open AccessInhibition of neutrophil elastase and cathepsin G as a new approach to the treatment of psoriasis: from fundamental biology to development of new target-specific drugs
Author(s) -
M.Yu. Krasavin Krasavin,
Maxim Gureev,
А. В. Гарабаджиу,
A. Yu. Pashkin,
А. С. Жуков,
В. Р. Хайрутдинов,
А. В. Самцов,
В. И. Швец
Publication year - 2019
Publication title -
doklady akademii nauk. rossijskaâ akademiâ nauk
Language(s) - English
Resource type - Journals
ISSN - 0869-5652
DOI - 10.31857/s0869-56524874455-459
Subject(s) - proteases , cathepsin g , psoriasis , elastase , neutrophil elastase , serine , computational biology , drug discovery , biology , cathepsin , pharmacology , biochemistry , enzyme , immunology , inflammation
Psoriasis therapy remains extremely relevant area of modern drug design, due to necessity of adverse reactions reduction, inherent for actual methods of therapy. It has been established that two of serine proteases are key agents in psoriasis development: neutrophil elastase 1 (HNE1) and cathepsin G (CatG). Collected molecular data for presented targets forms the basis of molecular modeling strategy for search and identification of new target-specific inhibitors. The result of work is a group of high-priority small-molecule compounds with double-targeted affinity with ability to suppress pro-psoriatic processes, induced by observed serine proteases in the initial stage of disease.